Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Herpes simplex virus type 1 ribonucleotide reductase large subunit (HSV-1 RR1)
- Target
- HSV-1 RR1
- Molecular classification
- Enzyme, Oxidoreductase (specifically, ribonucleotide reductase, large subunit)
01
Overview
Herpes simplex virus type 1 ribonucleotide reductase large subunit (HSV-1 RR1) is a 136,000–140,000 Da viral polypeptide forming part of the ribonucleotide reductase enzyme. Along with the small subunit (HSV-1 RR2), it catalyzes the reduction of ribonucleotides to deoxyribonucleotides, supplying essential precursors for viral DNA synthesis. HSV-1 RR1 possesses unique structural features, including a distinct N-terminal domain, and is indispensable for viral replication in non-dividing cells. Its absence impairs viral neurovirulence. Drugs targeting this enzyme have been developed to selectively inhibit viral replication with minimal impact on host enzymes.
- Other names
- HSV-1 RR1HSV ribonucleotide reductase large subunitHSV RR1
02
Mechanism of action
Inhibition of the enzyme’s catalytic activity, blocking viral DNA replication. Disruption of subunit association (targeting RR1-RR2 interface).
03
Biological functions
Catalysis of reduction of ribonucleotides to deoxyribonucleotides for viral DNA synthesisEssential for herpesvirus replication in non-dividing cellsPossible anti-apoptotic function
04
Disease associations
Infection (critical for herpes simplex virus type 1 pathology)Viral virulence and pathogenicity
05
Safety considerations
Host toxicity: Homologous host enzymes may also be affected by poorly selective inhibitorsResistance: Viral mutations leading to drug resistance can occur
06
Interacting drugs
Ribonucleotide reductase inhibitors (e.g., thiosemicarbazones, peptidomimetics)
1 more in the full profile.
07
Biomarkers
Viral ribonucleotide reductase activity (for viral infection and replication status)
Beyond the preview
Go deeper on Herpes simplex virus type 1 ribonucleotide reductase large subunit (HSV-1 RR1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Herpes simplex virus type 1 ribonucleotide reductase large subunit (HSV-1 RR1).